STOCK TITAN

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Sera Prognostics (Nasdaq: SERA) will report first quarter fiscal 2026 results on Wednesday, May 6, 2026, after market close and will host a conference call and live webcast at 5:00 p.m. ET. A press release with results and highlights will be distributed before the call.

Live audio and archived replay will be available on the company's Investors page at www.sera.com and the webcast will be archived for one year.

Loading...
Loading translation...

AI-generated analysis. Not financial advice.

Positive

  • None.

Negative

  • None.

News Market Reaction – SERA

-0.23%
1 alert
-0.23% News Effect

On the day this news was published, SERA declined 0.23%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Results date: May 6, 2026 Call time: 5:00 p.m. Eastern Time US dial-in: (800) 836-8184 +2 more
5 metrics
Results date May 6, 2026 Q1 FY 2026 financial results release after market close
Call time 5:00 p.m. Eastern Time Start time for Q1 FY 2026 conference call/webcast
US dial-in (800) 836-8184 Domestic access number for the Q1 FY 2026 earnings call
International dial-in (646) 357-8785 International access number for the Q1 FY 2026 earnings call
Webcast archive period 1 year Duration the Q1 FY 2026 webcast replay will remain available

Market Reality Check

Price: $2.16 Vol: Volume 9,424 is below 20-...
low vol
$2.16 Last Close
Volume Volume 9,424 is below 20-day average 42,537 (relative volume 0.22). low
Technical Trading below 200-day MA ($2.17 vs $2.84), reflecting prior weakness before this notice.

Peers on Argus

Before this call announcement, SERA was down 5.24%, while momentum peers were mi...
1 Up 1 Down

Before this call announcement, SERA was down 5.24%, while momentum peers were mixed: RCEL up 6.92% and LUCD down 2.34%, suggesting stock-specific factors rather than a uniform sector move.

Previous Conferences,earnings Reports

5 past events · Latest: Mar 04 (Neutral)
Same Type Pattern 5 events
Date Event Sentiment Move Catalyst
Mar 04 Earnings call scheduling Neutral -4.3% Set date and time for Q4 and FY 2025 results call and webcast.
Oct 30 Earnings call scheduling Neutral -2.1% Announced Q3 2025 results date with related conference call logistics.
Jul 29 Earnings call scheduling Neutral -1.0% Outlined Q2 2025 results timing and access numbers for investors.
Apr 24 Earnings call scheduling Neutral -2.0% Provided Q1 2025 results date, call time, and dial-in information.
Mar 11 Earnings call scheduling Neutral +1.9% Announced Q4 and FY 2024 results release and related webcast details.
Pattern Detected

Similar conference-call/earnings scheduling releases have led to modest average moves of -1.5%, with a slight negative bias.

Recent Company History

Over the past year, Sera frequently issued conference-call and webcast notices around quarterly and annual results, typically after market close at 5:00 p.m. ET. These announcements, tagged as conferences/earnings, have produced small share-price moves, averaging -1.5% over 5 events. Today’s first-quarter fiscal 2026 call notice follows the same pattern of pre-announcing timing and access details, fitting into an established communications cadence around financial disclosures.

Historical Comparison

-1.5% avg move · Past conferences/earnings call notices produced modest average moves of -1.5%, suggesting limited st...
conferences,earnings
-1.5%
Average Historical Move conferences,earnings

Past conferences/earnings call notices produced modest average moves of -1.5%, suggesting limited standalone impact from timing announcements.

Regular quarterly pattern of earnings call and webcast scheduling across fiscal 2024–2026.

Market Pulse Summary

This announcement schedules Sera’s Q1 FY 2026 results release for May 6, 2026 with a call at 5:00 p....
Analysis

This announcement schedules Sera’s Q1 FY 2026 results release for May 6, 2026 with a call at 5:00 p.m. ET, continuing a steady cadence of conference-call notices. Historically, such conferences/earnings tag releases have produced modest average moves of -1.5%. Investors may focus on previously reported cash levels, operating losses, and recent insider activity when evaluating upcoming results, with attention on how new disclosures compare to past filings.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

SALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report first quarter fiscal year 2026 financial results on Wednesday May 6, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

Conference Call Details:

US domestic callers: (800) 836-8184

International callers: (646) 357-8785

Webcast Registration Link: https://app.webinar.net/voeWlGmwyd6

Live audio of the webcast will be available online from the Investors page of the Company's website at www.sera.com. The webcast will be archived on the Investors page and will be available for one year.

About Sera Prognostics, Inc.

Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in Salt Lake City, Utah.

About Preterm Birth

Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2025 March of Dimes Report Card shows that, for the fourth consecutive year, the United States earned a D+ grade for preterm birth, making the longest stretch of the lowest grade in Report Card history. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children. The annual health care costs to manage short- and long-term complications of prematurity in the United States were estimated to be approximately $25 billion for 2016.

About the PreTRM® Test

The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM® Test is ordered by a medical professional.

Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the date and time and content of the Company's quarterly earnings release and conference call; availability of the live audio of the conference call on the Company's website; and the Company's strategic directives under the caption "About Sera Prognostics, Inc." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading "Risk Factors" contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. 

Investor Contact
Jennifer Zibuda, Head of Investor Relations
jzibuda@sera.com
+1 (801) 396-8043

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-announces-conference-call-and-webcast-of-first-quarter-fiscal-year-2026-financial-results-on-may-6-2026-302749482.html

SOURCE Sera Prognostics, Inc.

FAQ

When will SERA report Q1 fiscal 2026 results and what is the event schedule?

SERA will report Q1 fiscal 2026 results on May 6, 2026, after market close, with a webcast and conference call at 5:00 p.m. ET. According to the company, a press release with results will be distributed before the call and the audio will be available online.

How can investors join the SERA May 6, 2026 conference call and webcast?

Investors can join via the provided webcast registration link or by phone: (800) 836-8184 (US) and (646) 357-8785 (international). According to the company, live audio will stream from the Investors page at www.sera.com.

Will SERA's May 6, 2026 webcast be available after the live event and for how long?

Yes, the webcast will be archived and available for one year on the Investors page. According to the company, investors can access both the live audio during the call and the archived replay online for twelve months.

What topics will SERA cover during the May 6, 2026 earnings call for SERA stock?

The company will discuss operational highlights, financial results, and other key topics during the call. According to the company, management plans to review the quarter's performance and material updates relevant to shareholders.

Where can I find the press release with SERA's first quarter fiscal 2026 financial results?

The press release will be publicly distributed before the May 6, 2026 call and posted on the Investors page. According to the company, the release and the live webcast audio will both be available on www.sera.com.